JACKSONVILLE, Fla. - Johnson & Johnson has announced the expansion of its TECNIS Odyssey intraocular lens (IOL) across the U.S., a move aimed at enhancing vision for cataract patients. The TECNIS Odyssey IOL is designed to provide a full range of vision, potentially reducing the need for glasses post-surgery.
The TECNIS Odyssey IOL, which is part of Johnson & Johnson's presbyopia-correcting product line, is reported to allow patients to see clearly at various distances, from near to far, and is said to perform exceptionally in low light conditions. It is constructed on the TECNIS platform and claims to offer twice the contrast in dim lighting compared to the PanOptix IOL, along with the ability to read print 14% smaller on average.
According to the company, the majority of patients using the TECNIS Odyssey IOL experience minimal visual disturbances such as halos or glare following surgery. The product is also said to have a higher tolerance for residual refractive errors, which may contribute to consistent and reliable outcomes for patients.
Dr. George O. Waring IV, a paid consultant for Johnson & Johnson Vision, praised the TECNIS Odyssey IOL for its balance and comprehensive range of vision, stating it sets a new standard in the field.
This announcement follows reports that a significant portion of Americans aged 40 and above have cataracts, yet a smaller percentage have undergone surgery. The TECNIS Odyssey IOL aims to address vision issues like presbyopia at the time of cataract surgery.
Johnson & Johnson is also launching the "TECNIS Odyssey IOL Peer Connect" program, which aims to facilitate discussions among healthcare professionals about the technology.
The TECNIS Odyssey IOL has received regulatory approval in several countries, including Japan, the EU, Korea, Canada, Singapore, Australia, and New Zealand.
This expansion aligns with Johnson & Johnson's commitment to eye health and its broad portfolio of products designed to improve vision across various stages of life.
The information in this article is based on a press release statement.
In other recent news, Johnson & Johnson reported significant advancements in multiple myeloma treatments. The Phase 3 CARTITUDE-4 study revealed that CARVYKTI improves overall survival in patients with relapsed or lenalidomide-refractory multiple myeloma. Similarly, the Phase 3 AURIGA study demonstrated that DARZALEX FASPRO, in combination with lenalidomide, significantly improved patient outcomes.
The Phase 3 CEPHEUS study also showed promising results, indicating that DARZALEX FASPRO, combined with other drugs, improved patient outcomes. The Phase 1b RedirecTT-1 study revealed promising efficacy for a novel bispecific antibody combination therapy in treating relapsed or refractory multiple myeloma.
In legal developments, Johnson & Johnson's subsidiary, Red River Talc LLC, filed for a prepackaged Chapter 11 bankruptcy as part of an $8 billion settlement strategy to resolve ongoing ovarian cancer claims related to cosmetic talc litigation in the U.S. Goldman Sachs reiterated its Buy rating on shares of CG Oncology, following new data presented by Johnson & Johnson. Lastly, the company announced the retirement of Executive Vice President and Chief Human Resources Officer, Dr. Peter M. Fasolo, with Kristen Mulholland named as his successor. These are recent developments at Johnson & Johnson.
InvestingPro Insights
Johnson & Johnson's expansion of its TECNIS Odyssey intraocular lens across the U.S. aligns well with the company's strong market position and financial health. According to InvestingPro data, Johnson & Johnson boasts a substantial market capitalization of $388.53 billion, underscoring its position as a major player in the healthcare sector.
The company's focus on innovative products like the TECNIS Odyssey IOL is reflected in its solid financial performance. Johnson & Johnson reported a revenue of $86.58 billion in the last twelve months as of Q2 2024, with a revenue growth of 5.13% over the same period. This growth trajectory supports the company's ability to invest in and expand its product lines.
InvestingPro Tips highlight Johnson & Johnson's financial stability and shareholder-friendly policies. The company has raised its dividend for 53 consecutive years, demonstrating a long-term commitment to returning value to shareholders. This consistent dividend growth, coupled with a current dividend yield of 3.07%, makes Johnson & Johnson an attractive option for income-focused investors.
Moreover, Johnson & Johnson's stock is trading near its 52-week high, which could indicate market confidence in the company's recent moves, including the expansion of the TECNIS Odyssey IOL. The company's strong gross profit margin of 69.43% suggests efficient operations and pricing power, which could be beneficial as it rolls out new products in the competitive healthcare market.
For investors interested in a deeper analysis, InvestingPro offers 11 additional tips for Johnson & Johnson, providing a comprehensive view of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.